Skip to main content
ANAVEX LIFE SCIENCES CORP. logo

ANAVEX LIFE SCIENCES CORP. — Investor Relations & Filings

Ticker · AVXL ISIN · US0327973006 LEI · 549300K1I5L8COCQ8W36 US Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2026-05-22 Delisting Announcement
Country US United States of America
Listing US AVXL

About ANAVEX LIFE SCIENCES CORP.

https://www.anavex.com

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for central nervous system (CNS) disorders. The company develops targeted drug candidates for neurodegenerative and neurodevelopmental diseases, including Alzheimer's disease, Parkinson's disease, and Rett syndrome. Anavex's approach is centered on precision medicine, utilizing small molecule drugs designed to restore cellular homeostasis. Its lead investigational compound, blarcamesine (ANAVEX®2-73), is an orally available sigma-1 receptor (S1R) agonist being evaluated for its potential to treat a range of neurological conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Delisting Announcement Classification · 98% confidence The document is a Form 8-K current report containing Item 3.01 “Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing,” which is an official notice from Nasdaq regarding non-compliance with listing rules and potential delisting. This aligns with the Delisting Announcement category.
2026-05-22 English
FORM 8-K
Board/Management Information Classification · 94% confidence The document is a Form 8-K “Current Report” under Item 5.02, describing the departure of the Chief Operating Officer and appointment of an Interim CEO. It is an announcement of management changes (senior officer departure/appointment) rather than a financial report or other filing type. This fits the Board/Management Information category.
2026-05-15 English
8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, specifically reporting Item 5.02 which covers the termination of the CEO and appointment of an interim CEO. This pertains to changes in the company’s senior management, fitting the Board/Management Information category.
2026-05-06 English
8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 20, 2026, by Anavex Life Sciences Corp. The key content is the appointment of a new board member, Axel Paeger, MD, MBA, MBI, effective February 23, 2026. The document includes details about the director's independence, compensation, and related disclosures. There is no financial data or earnings information, nor is it an announcement of a report publication. The primary subject is a change in the company's board of directors. Therefore, the document fits the category of Board/Management Information (MANG). The document length is about 5107 characters, which is consistent with a detailed 8-K filing for management changes rather than a brief announcement or a full report.
2026-02-25 English
10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
Interim / Quarterly Report Q1 2026
2026-02-09 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 9, 2026, by Anavex Life Sciences Corp. It reports the issuance of a press release containing financial results for the fiscal quarter ended December 31, 2025. The document explicitly states that the press release is furnished as Exhibit 99.1 and is incorporated by reference. The text does not contain the actual financial results or detailed financial statements but rather announces the release of such information. The document length is 4106 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (press release of quarterly financial results) rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER), as the press release reports quarterly financial results, and the 8-K serves as the official filing of that release.
2026-02-09 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.